acute myeloid leukaemia

News

EHA: Survival data sets Daiichi Sankyo's quizartinib back on...

Three years after Daiichi Sankyo's FLT3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial that is key to getting the drug to the U

News

FDA clears new first-line use for Servier's Tibsovo in AML

Servier is on course to get a return on its $1.8 billion takeover of Agios Pharma's oncology business after getting a key FDA approval for Tibsovo, the main asset in the deal.

News

Nkarta leaps on early CAR-NK data in blood cancers

Shares in Nkarta more than doubled yesterday on the results of early-stage clinical that suggested it could be on to a winner with its natural kill (NK) cell therapy platform.

News

Blue Note leukaemia DTx gets FDA breakthrough tag

A prescription digital therapeutic (DTx) for leukaemia patients developed by Blue Note Therapeutics has been awarded breakthrough device status by the FDA.

News

BMS cuts $3.15bn deal with Century for cancer cell therapies

Bristol-Myers Squibb chief executive Giovanni Caforio has promised to invest in the company's pipeline at the virtual JP Morgan Healthcare Conference, and demonstrated that commitment by li

News